RayBerganMD

Oncology • Omaha, NE

Genitourinary Oncology

Deputy Director, Fred & Pamela Buffett Cancer Center, Professor Eppley Cancer Institute

Join to view full profile

Dr. Bergan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bergan's full profile

Already have an account?

Office
986805 Nebraska Medical Center
Omaha, NE 68198
Phone+1 402-559-9536

Fax+1 402-559-4238

Summary

Dr. Ray Bergan is a medical oncologist and basic cancer scientist in Omaha, NE and is affiliated with the Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center. He completed fellowships in medical oncology and drug discovery from the National Cancer Institute, Bethesda, MD. He specializes in early phase therapeutics, genitourinary cancer and cancer prevention.

Clinical Expertise

Genitourinary cancer, Preventive medicine, Clinical research, Laboratory research, Medical oncology

Education & Training

University of Nebraska Medical Centercurrently matriculated, Academic Leaders Course, 2021 - 2022
Harvard, T.H. Chan School of Public HealthCertificate of Completion, Leadership Development Course, 2015 - 2015
National Cancer InstituteLab research, cell biology, 1993 - 1998
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1987 - 1990
SUNY Upstate Medical UniversityClass of 1987

Certifications & Licensure

NE State Medical License 2020 - 2026
OR State Medical License 2015 - 2023
IL State Medical License 1998 - 2017
MD State Medical License 1991 - 1998
American Board of Internal Medicine Medical Oncology

Clinical Trials

Iloprost in Preventing Lung Cancer in Former Smokers Start of enrollment: 2015 Nov 05
Completed
Phase 1
The Registry of Oncology Outcomes Associated With Testing and Treatment Start of enrollment: 2021 May 05
Recruiting
Oltipraz in the Prevention of Lung Cancer in People Who Smoke Start of enrollment: 2000 Aug 01
Completed
Phase 1
Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy Start of enrollment: 2002 Dec 01
Terminated
Phase 2
Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants Start of enrollment: 2011 Nov 01
Completed
Phase 1
Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients Start of enrollment: 2007 Jul 01
Completed
Phase 1
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Start of enrollment: 2020 Apr 01
Terminated
Phase 1
Clinical Trial of Green Tea Catechins in Men on Active Surveillance Start of enrollment: 2020 Aug 21
Recruiting
Phase 2
Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission Start of enrollment: 2016 Jun 16
Completed
Phase 1
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Active, not recruiting
Phase 3
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy Start of enrollment: 2015 Oct 01
Completed
Phase 2
Genistein in Treating Patients With Prostate Cancer Start of enrollment: 2011 Feb 03
Terminated
Phase 2
Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia Start of enrollment: 2010 Oct 01
Terminated
Phase 1, Phase 2
Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung Start of enrollment: 2009 Oct 01
Terminated
Phase 1
Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer Start of enrollment: 2009 Oct 01
Completed
Phase 2
Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer Start of enrollment: 2007 Mar 01
Completed
Phase 2
4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Start of enrollment: 2009 Dec 01
Completed
Phase 2
Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia Start of enrollment: 2008 Mar 01
Terminated
Phase 1
Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer Start of enrollment: 2006 Jan 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

16 citations
Endoglin-Mediated Suppression of Prostate Cancer Invasion Is Regulated by Activin and Bone Morphogenetic Protein Type II Receptors
Michael J. Breen, Diarmuid M. Moran, Wenzhe Liu, Xiaoke Huang, Calvin P.H. Vary
Plos One. 2013-08-13
38 citations
A Phase I Trial of Berberine in Chinese with Ulcerative Colitis
Li Xu, Yujie Zhang, Xianmin Xue, Jie Liu, Zeng Shan Li
Cancer Prevention Research. 2020-01-01
37 citations
The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine.
Dane Dickson, Jennifer E. Johnson, Raymond C. Bergan, Rebecca Owens, Vivek Subbiah
Cell. 2020-01-09

Authored Content

Assessing the State of Cancer Research: Insights from an Innovative Clinician-ScientistFebruary 2022
Assessing the State of Cancer Research: Insights from an Innovative Clinician-ScientistFebruary 2022

Press Mentions

Assessing the State of Cancer Research: Insights from an Innovative Clinician-ScientistJuly 10th, 2022
Why Your Doctor Should Also Be a ScientistJuly 10th, 2022

Grant Support

Fred & Pamela Buffett Cancer CenterNational Cancer Institute2021–2026
Inhibiting Bone Destruction by Prostate Cancer with Dual-Acting Bone-Defending AgentsDOD, Prostate Cancer Research Program, Idea Development Award2020–2023
Knight Cancer InstituteNational Cancer Institute2017–2022
The Quantitation of Protein Interactions in Cancer CellsNIH2016–2021
Serial Measurement of Molecular Architecture and Response to TherapyProspect Creek Foundation2016–2019
Inhibiting prostate cancer cell motilityDepartment of Defense, Prostate Cancer Research Program, Laboratory-Clinical Transition Award2015–2019
Therapeutically targeting cancer cell motilityVeterans Administration Merit Award2015–2019
NCI Community Oncology Research ProgramNIH/NCI2015–2019
Phase I study of berberine in inflammatory bowel disease (China-based clinical trial)NIH/NCI2015–2018
Discovery of Selective MAP2K4 Inhibitors to Target MetastasisNIH/NCI2015–2018
Rapid identification of tumor cells, immune reactivity and drug response via microfiltration of cancer patient bloodDefense Advanced Research Projects Agency2015–2017
Cancer Prevention Agent Development Program: Early Phase Clinical ResearchNIH/NCI2012–2015
Robert H. Lurie Cancer CancerNIH/NCI2001–2015
Genistein-mediated regulation of prostate cancer cell motilityNIH/NCI2008–2014
Prostate SPORENIH/NCI2003–2014
Biomarker Identification Core, Prevention CenterNIH/NCI2003–2014
Center of Excellence for Chemoprevention Drug Development: Phase 1 and Phase 2 Clinical Trials of Cancer Chemopreventive AgentsNIH/NCI2003–2014
TiO2 Nanocomposites for Targeted Treatment and Imaging of Prostate Cancer, Nanomaterials for Cancer Diagnostics and Therapeutics CenterNIH/NCI2006–2010
Regulation and Modulation of Prostate Cell MetastasisVA Merit Review Award2004–2009
Molecular Correlates of Soy in HumansNIH/NCI2002–2005
Clinical Phase I Multiple Dose Safety Study of the Combination of NAC and Oltipraz in SmokersNIH/NCI1999–2004